News Search Results
Mar 25, 2026, 07:00 ET Bioptimus Announces STELA: The World's Largest Clinically Linked Spatial Biology Atlas, alongside key partners 10x Genomics and Broad Clinical Labs
www.bioptimus.comMedia Contact: [email protected] 10x Genomics10x Genomics is a life science technology company building products to accelerate the mastery of biology and advance human health. Our integrated
More news about: Bioptimus
Mar 17, 2026, 08:00 ET PerturbAI Launches from Stealth, Unveils the World's Largest In Vivo CRISPR Atlas
- Dataset of 8 million brain-wide cells, generated and analyzed in collaboration with NVIDIA, Allen Institute for Brain Science and 10x Genomics, establishes the largest causal map of gene function in living tissue, showcasing the power of PerturbAI's scalable discovery
More news about: PerturbAI
Feb 19, 2026, 16:05 ET 10x Genomics to Participate in the 46th Annual TD Cowen Health Care Conference
https://investors.10xgenomics.com/. The webcast will be archived and available for replay for at least 30 days after the event.About 10x Genomics10x Genomics is a life science technology company building products to accelerate the mastery of biology and advance human health. Our integrated
More news about: 10x Genomics, Inc.
Feb 12, 2026, 22:20 ET Omics Empower 香港實驗室正式推出 Xenium™ 原位空間轉錄組服務
降解風險並維持細胞活力，從而支持高品質單細胞數據的生成，同時提升專案溝通與執行效率。Xenium™ 由 10x Genomics 開發，可在保留組織空間結構的前提下，對 RNA 分子進行原位定位與定量分析，實現單細胞及亞細胞層級解析度。該技術廣泛應用於腫瘤微環境研究、神經科學、免疫學及轉譯醫學等領域，有助於研究人員解析細胞在原位環境中的分子特徵與空間組織關係。據公開資料顯示，Omics Empower 香港實驗室為全港第二家運行 Xenium 平台的實驗室，進一步擴展本地高端空間轉錄組技術的應用能力。除 Xenium™ 外，香港實驗室亦支援 10x Genomics Visium 全轉錄組空間分析，以及由 BGI 集團開發的
More news about: Omics Empower
Feb 12, 2026, 16:05 ET 10x Genomics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Outlook for 2026
should not be relied upon as representing 10x Genomics, Inc.'s views as of any date subsequent to the date of this press release. 10x Genomics, Inc. disclaims any obligation to update any forward-looking statements provided to reflect any change in 10x Genomics' expectations or any change in events, conditions
More news about: 10x Genomics, Inc.
Feb 04, 2026, 09:00 ET PharosAI and 10x Genomics Partner to Transform Cancer Research with AI and Spatial Biology
should not be relied upon as representing 10x Genomics, Inc.'s views as of any date subsequent to the date of this press release. 10x Genomics, Inc. disclaims any obligation to update any forward-looking statements provided to reflect any change in 10x Genomics' expectations or any change in events, conditions
More news about: 10x Genomics, Inc.
Jan 22, 2026, 16:05 ET 10x Genomics to Report Fourth Quarter and Full Year 2025 Financial Results on February 12, 2026
https://investors.10xgenomics.com/. The webcast will be archived and available for replay for at least 45 days after the event.About 10x Genomics10x Genomics is a life science technology company building products to accelerate the mastery of biology and advance human health. Our integrated
More news about: 10x Genomics, Inc.
Jan 22, 2026, 10:30 ET Next-Generation Sequencing Market worth $29.53 billion by 2030 | MarketsandMarkets™
Scientific (Luxembourg), PacBio (US), Oxford Nanopore Technologies plc. (UK), Takara Bio Inc. (Japan), BGI Group (China), Merck KGaA (Germany), BD (US), 10X Genomics (US), New England Biolabs (US), Promega Corporation (US), Novogene Co., Ltd. (China), LGC Limited (UK), WuXi Biologics (China), MGI Tech Co. Ltd.
More news about: MarketsandMarkets
Jan 12, 2026, 09:11 ET 10x Genomics Launches Study to Advance Research in Blood-Based Diagnostics for Autoimmune Disease
should not be relied upon as representing 10x Genomics, Inc.'s views as of any date subsequent to the date of this press release. 10x Genomics, Inc. disclaims any obligation to update any forward-looking statements provided to reflect any change in 10x Genomics' expectations or any change in events, conditions
More news about: 10x Genomics, Inc.
Jan 12, 2026, 09:10 ET 10x Genomics to Advance Research in Diagnostic Applications of Tumor Single Cell and Spatial Profiling
should not be relied upon as representing 10x Genomics, Inc.'s views as of any date subsequent to the date of this press release. 10x Genomics, Inc. disclaims any obligation to update any forward-looking statements provided to reflect any change in 10x Genomics' expectations or any change in events, conditions
More news about: 10x Genomics, Inc.
Jan 12, 2026, 09:00 ET Cancer Research Institute Launches Transformative AI-Driven Immuno-Oncology Initiative Powered by 10x Genomics Technology
should not be relied upon as representing 10x Genomics, Inc.'s views as of any date subsequent to the date of this press release. 10x Genomics, Inc. disclaims any obligation to update any forward-looking statements provided to reflect any change in 10x Genomics' expectations or any change in events, conditions
More news about: 10x Genomics, Inc.
Jan 11, 2026, 12:00 ET 10x Genomics Announces Preliminary Select Fourth Quarter and Full Year 2025 Results
recently-filed 10-K, 10-Q and elsewhere in the documents 10x Genomics, Inc. files with the Securities and Exchange Commission from time to time. 10x Genomics' products are for research use only (RUO) and are not for use in diagnostic procedures. "10x Genomics", "Chromium" and "Xenium" are trademarks of 10x. 10x
More news about: 10x Genomics, Inc.
Dec 29, 2025, 16:05 ET 10x Genomics to Present at the 44th Annual J.P. Morgan Healthcare Conference
https://investors.10xgenomics.com/. The webcast will be archived and available for replay for at least 30 days after the event.About 10x Genomics10x Genomics is a life science technology company building products to accelerate the mastery of biology and advance human health. Our integrated
More news about: 10x Genomics, Inc.
Nov 20, 2025, 10:01 ET Genomics Market worth $85.09 billion by 2030 with 12.6% CAGR | MarketsandMarkets™
Nanopore Technologies Plc. (UK), Takara Bio Inc. (Japan), BGI Group (China), Eppendorf SE (Germany), Merck KGaA (Germany), BD (US), Abbott (US), 10X Genomics, Inc. (US), New England Biolabs (US), Promega Corporation (US), Creative Biogene (US), Novogene Co., Ltd. (China), Helix, Inc. (US), Phalanx Biotech
More news about: MarketsandMarkets
Nov 18, 2025, 09:00 ET New ASTRA Consortium Unites Asia-Pacific Scientists to Build Pan-Cancer Spatial Atlas Powered by 10x Genomics' Xenium
outline plans to scale the atlas across cancer types, institutions, and regional hubs. About 10x Genomics10x Genomics is a life science technology company building products to accelerate the mastery of biology and advance human health. Our integrated
More news about: 10x Genomics, Inc.
Nov 11, 2025, 16:05 ET 10x Genomics to Participate in the Wolfe Research Healthcare Conference 2025
archived and available for replay for at least 30 days after the event. About 10x Genomics 10x Genomics is a life science technology company building products to accelerate the mastery of biology and advance human health.
More news about: 10x Genomics, Inc.
Nov 06, 2025, 16:05 ET 10x Genomics Reports Third Quarter 2025 Financial Results
should not be relied upon as representing 10x Genomics, Inc.'s views as of any date subsequent to the date of this press release. 10x Genomics, Inc. disclaims any obligation to update any forward-looking statements provided to reflect any change in 10x Genomics' expectations or any change in events, conditions
More news about: 10x Genomics, Inc.
Oct 29, 2025, 09:00 ET 10x Genomics Launches the Next Generation of Chromium Flex to Empower Scientists to Massively Scale Single Cell Research
10xgenomics.com or contact your 10x Genomics representative. About 10x Genomics10x Genomics is a life science technology company building products to accelerate the mastery of biology
More news about: 10x Genomics, Inc.
Oct 24, 2025, 06:22 ET Weekly Recap: 12 Tech Press Releases You Need to See
10x Genomics and Anthropic Partner to Make Single Cell and Spatial Analysis More Accessible Through Claude for Life Sciences Using
More news about: PR Newswire
Oct 20, 2025, 12:30 ET 10x Genomics and Anthropic Partner to Make Single Cell and Spatial Analysis More Accessible Through Claude for Life Sciences
should not be relied upon as representing 10x Genomics, Inc.'s views as of any date subsequent to the date of this press release. 10x Genomics, Inc. disclaims any obligation to update any forward-looking statements provided to reflect any change in 10x Genomics' expectations or any change in events, conditions
More news about: 10x Genomics, Inc.
Oct 16, 2025, 14:02 ET Alamar Biosciences élargit son équipe de direction pour assurer la prochaine phase de croissance
25 ans d'expérience en matière de leadership opérationnel et financier dans divers secteurs et a joué un rôle déterminant dans l'entrée en bourse de 10x Genomics en 2019, dont il a été le directeur financier pendant plus de cinq ans. Justin a occupé pendant plus de trois ans le poste de vice-président des
More news about: Alamar Biosciences, Inc.
Oct 16, 2025, 14:01 ET Alamar Biosciences erweitert die Führungsspitze für die nächste Wachstumsphase
Erfahrung in leitenden Positionen im operativen und finanziellen Bereich in verschiedenen Branchen und war maßgeblich an der Börsennotierung von 10x Genomics im Jahr 2019 beteiligt, wo er über fünf Jahre lang als Finanzleiter tätig war. Justin war über drei Jahre lang als Vizepräsident für weltweite Finanzen
More news about: Alamar Biosciences, Inc.
Oct 16, 2025, 14:00 ET Alamar Biosciences amplía su liderazgo ejecutivo para impulsar la siguiente fase de crecimiento
financiero. Justin aporta más de 25 años de experiencia en liderazgo operativo y financiero en diversos sectores y fue clave para la salida a bolsa de 10x Genomics en 2019, ejerciendo como su director financiero durante más de cinco años. Justin fue vicepresidente de Finanzas y Operaciones Mundiales de Tesla
More news about: Alamar Biosciences, Inc.
Oct 16, 2025, 13:59 ET Alamar Biosciences расширяет руководящий штат для обеспечения следующего этапа роста
директора. Джастин обладает более чем 25-летним опытом операционного и финансового руководства в различных секторах и сыграл важную роль в преобразовании 10X Genomics в акционерную компанию в 2019 году, проработав в качестве ее финансового директора более пяти лет. Джастин более 3 лет занимал должность вице-президента
More news about: Alamar Biosciences, Inc.
Oct 16, 2025, 13:58 ET Spoločnosť Alamar Biosciences rozširuje svoje výkonné vedenie, aby zvládla ďalšiu fázu rastu
riaditeľa. Justin má viac ako 25-ročné skúsenosti s prevádzkovým a finančným vedením v rôznych sektoroch a zohral kľúčovú úlohu pri vstupe spoločnosti 10x Genomics na burzu v roku 2019, keď viac ako päť rokov pôsobil ako jej finančný riaditeľ. Justin zastával viac ako 3 roky pozíciu viceprezidenta spoločnosti
More news about: Alamar Biosciences, Inc.